Therapeutic strategies that restore SPLUNC1-βENaC interactions in CF airways, such as raising airway surface liquid pH, may not only limit ENaC hyperactivity but could also reduce levels of bacterial infections by placing SPLUNC1 at the apical plasma membrane. Here, BPIFA1 is linked to bacterial infectious disease.